Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Lung Cancer Patients, Caregivers
Interventions: There are no interventions in this study. All participants complete online surveys.; Other
Lead sponsor: LUNGevity Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Severe Eosinophilic Asthma, Nasal Polyps
Interventions: FASENRA(benralizumab); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more

Conditions: Hepatic Impairment
Interventions: Cotadutide; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Hialeah, Florida • San Antonio, Texas

Conditions: Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Selumetinib; Other · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Kidney Disease
Interventions: Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: No Intervention; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Asthma
Interventions: AMAZE™ Application, AMAZE™ Dashboard; Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Treatment A, Treatment B, Treatment C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hyperkalaemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: West Palm Beach, Florida

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

About this AstraZeneca sponsor directory page